Oncology experts roundtable: Practical insights on FDA draft guidance discussing OS data in cancer trials
Hosted by former EMA regulator Sinan B. Sarac, M.D., Ph.D., SVP Head of Oncology Europe at Parexel, this roundtable discusses the recently published FDA draft guidance "Approaches to Assessment of Overall Survival in Oncology Clinical Trials.” Sinan is joined by Bernardo Haddock Lobo Goulart, M.D., VP Parexel Regulatory Consulting and former FDA regulator, and Aaron Sosa, M.D., VP Parexel Regulatory Consulting and former EMA regulator.
The FDA's new draft guidance establishes overall survival (OS) as both an efficacy and safety endpoint in oncology trials, requiring its assessment even when not the primary endpoint. Parexel's oncology experts emphasize that sponsors must pre-specify OS analysis in statistical plans with clear harm thresholds to ensure surrogate endpoints don't mask potential harm. Both FDA and EMA are aligned in this approach, recognizing that while OS may not always be feasible as a primary endpoint, it remains central to regulatory evaluation and benefit-risk assessment.
Related Insights
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Blog
Actioning the commitment letter: The PDUFA VIII changes that matter most to sponsors
Aug 25, 2026
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Aug 19, 2026
Blog
The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape
Aug 12, 2026
Webinar
From APAC to global: Designing data that travels
Jul 16, 2026
Blog
Regulatory submissions as a source of insight: How AI can amplify the value of our work
Jul 15, 2026
Blog
Accelerating first-in-human studies: Why the FDA’s Expedited IND pilot signals a new era for early development
Jul 6, 2026
CTB Blog
A credible global regulatory strategy is an early-phase imperative, not a late-stage commercial exercise
Jun 23, 2026
CTB Blog
Understanding FDA complete response letters: Why CMC readiness must become a strategic priority
Jun 18, 2026
Case Study
Case study: Repositioning first-in-human development at speed
Jun 8, 2026
Blog
Beyond participation: How EU HTA is turning patient and clinician engagement into evidence architecture
May 26, 2026
Related Insights
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
Case Study
Speed meets strategy: Delivering a critical FDA 1572 package in just seven days
Sep 9, 2026
Blog
Actioning the commitment letter: The PDUFA VIII changes that matter most to sponsors
Aug 25, 2026
Blog
Data without borders: Assessing China-only evidence for EMA approval – insights from ex-EMA and seasoned subject matter experts
Aug 19, 2026
Blog
The Next Frontier of ADC Development: Navigating an Evolving Regulatory Landscape
Aug 12, 2026
Webinar
From APAC to global: Designing data that travels
Jul 16, 2026
Blog
Regulatory submissions as a source of insight: How AI can amplify the value of our work
Jul 15, 2026
Blog
Accelerating first-in-human studies: Why the FDA’s Expedited IND pilot signals a new era for early development
Jul 6, 2026
CTB Blog
A credible global regulatory strategy is an early-phase imperative, not a late-stage commercial exercise
Jun 23, 2026
CTB Blog
Understanding FDA complete response letters: Why CMC readiness must become a strategic priority
Jun 18, 2026
Case Study
Case study: Repositioning first-in-human development at speed
Jun 8, 2026
Blog
Beyond participation: How EU HTA is turning patient and clinician engagement into evidence architecture
May 26, 2026